EARNEST Partners’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$139M Buy
886,634
+1,344
+0.2% +$201K 0.5% 78
2026
Q1
$135M Sell
885,290
-36,106
-4% -$5.53M 0.56% 63
2025
Q4
$127M Buy
921,396
+81,370
+10% +$10.7M 0.54% 73
2025
Q3
$108M Sell
840,026
-10,181
-1% -$1.24M 0.47% 83
2025
Q2
$103M Buy
850,207
+25,836
+3% +$2.91M 0.46% 79
2025
Q1
$91.9M Buy
824,371
+28,460
+4% +$3.03M 0.44% 90
2024
Q4
$77.5M Sell
795,911
-13,236
-2% -$1.41M 0.35% 113
2024
Q3
$93.1M Sell
809,147
-140
-0% -$15.9K 0.41% 98
2024
Q2
$86.2M Sell
809,287
-26,264
-3% -$2.64M 0.4% 100
2024
Q1
$80.8M Buy
835,551
+21,535
+3% +$2.21M 0.37% 103
2023
Q4
$82.2M Sell
814,016
-1,822
-0.2% -$176K 0.41% 99
2023
Q3
$83.1M Sell
815,838
-24,170
-3% -$2.45M 0.48% 88
2023
Q2
$84.8M Sell
840,008
-10,754
-1% -$1.08M 0.47% 84
2023
Q1
$78.3M Sell
850,762
-6,315
-0.7% -$552K 0.45% 97
2022
Q4
$77.8M Sell
857,077
-14,641
-2% -$1.23M 0.48% 92
2022
Q3
$66.3M Buy
871,718
+4,784
+0.6% +$397K 0.45% 96
2022
Q2
$73.3M Sell
866,934
-26,592
-3% -$2.33M 0.49% 87
2022
Q1
$78.4M Sell
893,526
-11,292
-1% -$978K 0.46% 90
2021
Q4
$79.1M Sell
904,818
-37,394
-4% -$3.1M 0.46% 85
2021
Q3
$77.1M Sell
942,212
-53,037
-5% -$4.77M 0.47% 85
2021
Q2
$90.8M Sell
995,249
-77,132
-7% -$6.87M 0.53% 77
2021
Q1
$91.7M Buy
1,072,381
+79,658
+8% +$7.15M 0.55% 71
2020
Q4
$93.7M Buy
992,723
+20,661
+2% +$1.81M 0.65% 66
2020
Q3
$84.5M Sell
972,062
-18,518
-2% -$1.6M 0.73% 53
2020
Q2
$86.5M Sell
990,580
-342,241
-26% -$29.5M 0.82% 45
2020
Q1
$110M Sell
1,332,821
-569,158
-30% -$50.8M 1.24% 18
2019
Q4
$180M Sell
1,901,979
-38,288
-2% -$3.44M 1.42% 7
2019
Q3
$169M Buy
1,940,267
+11,281
+0.6% +$1.01M 1.52% 8
2019
Q2
$176M Sell
1,928,986
-246,689
-11% -$20.9M 1.59% 6
2019
Q1
$187M Buy
2,175,675
+28,205
+1% +$2.26M 1.79% 3
2018
Q4
$165M Sell
2,147,470
-29,796
-1% -$2.32M 1.8% 2
2018
Q3
$168M Sell
2,177,266
-25,439
-1% -$1.88M 1.51% 5
2018
Q2
$149M Buy
2,202,705
+3,684
+0.2% +$254K 1.39% 9
2018
Q1
$159M Sell
2,199,021
-30,510
-1% -$2.32M 1.51% 9
2017
Q4
$168M Sell
2,229,531
-9,463
-0.4% -$714K 1.61% 9
2017
Q3
$172M Sell
2,238,994
-48,871
-2% -$3.69M 1.72% 7
2017
Q2
$171M Sell
2,287,865
-24,876
-1% -$1.76M 1.8% 7
2017
Q1
$154M Sell
2,312,741
-11,322
-0.5% -$754K 1.64% 10
2016
Q4
$152M Buy
2,324,063
+322,585
+16% +$20.9M 1.66% 6
2016
Q3
$142M Sell
2,001,478
-83,543
-4% -$6.09M 1.49% 8
2016
Q2
$154M Sell
2,085,021
-274,541
-12% -$19M 1.67% 8
2016
Q1
$153M Sell
2,359,562
-58,818
-2% -$4M 1.6% 9
2015
Q4
$186M Sell
2,418,380
-73,943
-3% -$5.87M 1.9% 7
2015
Q3
$205M Buy
2,492,323
+10,660
+0.4% +$949K 2.02% 7
2015
Q2
$219M Buy
2,481,663
+64,968
+3% +$5.96M 1.91% 7
2015
Q1
$214M Sell
2,416,695
-99,403
-4% -$8.82M 1.84% 6
2014
Q4
$209M Buy
2,516,098
+52,570
+2% +$4.36M 1.71% 8
2014
Q3
$208M Sell
2,463,528
-144,141
-6% -$11.7M 1.74% 6
2014
Q2
$212M Sell
2,607,669
-38,317
-1% -$3.01M 1.68% 6
2014
Q1
$202M Buy
2,645,986
+76,554
+3% +$5.58M 1.62% 6
2013
Q4
$185M Buy
+2,569,432
New +$179M 1.48% 10

Other funds holding NVS

EARNEST Partners's NVS Position: Q2 2026 in Review

EARNEST Partners increased its Novartis (NVS) stake by 0.15% in Q2 2026, buying an estimated $201K and bringing the position to 886,634 shares worth $139M. The position accounts for 0.5% of the portfolio, ranked #78.

EARNEST Partners first reported a position in NVS in Q4 2013 and has held it in 51 quarters since. The position peaked at $219M in Q2 2015. 1,611 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • EARNEST Partners held 886,634 shares of Novartis worth $139M as of Q2 2026.
  • EARNEST Partners bought 1,344 Novartis shares in Q2 2026, an estimated $201K.
  • Novartis made up 0.5% of EARNEST Partners's portfolio in Q2 2026, its #78 holding.
  • EARNEST Partners first reported a position in Novartis in Q4 2013 and has held it in 51 quarters since.
  • EARNEST Partners's Novartis position peaked at $219M in Q2 2015.
  • 1,611 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on EARNEST Partners's 13F filing for Q2 2026, filed 13 Aug 2026.